Psoriatic Juvenile Idiopathic Arthritis Associated with Uveitis: A Case Report

Moretti, Davide; Cianchi, Ilaria; Vannucci, Gianfranco; Cimaz, Rolando; Simonini, Gabriele

doi:10.1155/2013/595890

Cited by 6 publications

(12 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adalimumab was also shown to be effective in a patient with psoriatic JIA and uveitis failing NSAID, MTX and etanercept therapy, resulting in remission of both conditions (56) and, in another case report, adalimumab was effective in a patient with AS and Behcet's disease (57).…”

Section: Adalimumab Clinical Data In Patients With Two or Moreimidsmentioning

confidence: 96%

Adalimumab in the Treatment of Immune-Mediated Diseases

Lapadula

Marchesoni

Armuzzi³

et al. 2014

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Tumour necrosis factor (TNF) plays an important role in the pathogenesis of immune-mediated inflammatory diseases (IMIDs). TNF inhibition results in down-regulation of abnormal and progressive inflammatory processes, resulting in rapid and sustained clinical remission, improved quality of life and prevention of target organ damage. Adalimumab is the first fully human monoclonal antibody directed against TNF. In this article, we review the role and cost effectiveness of adalimumab in the treatment of IMIDs in adults and children. The efficacy and tolerability of adalimumab has been demonstrated in patients with a wide range of inflammatory conditions, leading to regulatory approval in rheumatoid arthritis (RA), psoriatic arthritis (PsA), plaque psoriasis, inflammatory bowel diseases (Crohn's disease, ulcerative colitis, paediatric Crohn's disease, and intestinal Beheet's disease), ankylosing spondylitis (AS), axial spondyloarthritis (SpA) and juvenile idiopathic arthritis. The major tolerability issues with adalimumab are class effects, such as injection site reactions and increased risk of infection and lymphoma. As with all anti-TNF agents, adalimumab is immunogenic, although less than infliximab, and some patients receiving long-term adalimumab will develop anti-drug antibodies, causing a loss of response. Comparisons of its clinical utility and cost effectiveness have shown it to be a valid treatment choice in a wide range of patients. Recent data from Italian economic studies show the cost effectiveness

show abstract

Section: Adalimumab Clinical Data In Patients With Two or Moreimidsmentioning

confidence: 96%

Adalimumab in the Treatment of Immune-Mediated Diseases

Lapadula

Marchesoni

Armuzzi³

et al. 2014

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

show abstract

“…Only two case reports describe the use of adalimumab in pediatric psoriasis [ 85 ]. In these patients, adalimumab was prescribed after failure of other systemic agents and demonstrated a favorable outcome [ 112 , 113 ]. A multicenter, randomized, double-blind study evaluating the efficacy of adalimumab versus methotrexate in pediatric patients aged 4–17 years with chronic plaque psoriasis has been completed [ 114 ], although results are not currently available.…”

Section: Systemic Treatments and Biologicsmentioning

confidence: 99%

Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities

et al. 2015

View full text Add to dashboard Cite

Psoriasis is a common chronic immune-mediated inflammatory skin disorder and begins in childhood in almost one-third of the cases. Although children present with the same clinical subtypes of psoriasis seen in adults, lesions may differ in distribution and morphology, and their clinical symptoms at presentation may vary from those reported by adult patients. Nevertheless, diagnosis of psoriasis is primarily based on clinical features. Pediatric psoriasis can have a profound long-term impact on the psychological health of affected children. Additionally, pediatric psoriasis has been associated with certain comorbidities, such as obesity, hypertension, hyperlipidemia, diabetes mellitus and rheumatoid arthritis, making early diagnosis and management essential. As guidelines are lacking and most (systemic) treatments are not approved for use in children, treatment of pediatric psoriasis remains a challenge. A prospective, multicenter, international registry is needed to evaluate these treatments in a standardized manner and ultimately to develop international guidelines on pediatric psoriasis. This article reviews current concepts in pediatric psoriasis including epidemiology, clinical features, diagnosis, the role of topical and systemic agents and the association with other morbidities in childhood.

show abstract

“…This study was excluded because of systemic combination therapy. Current literature search revealed three new studies . One study was excluded because separate data on paediatric psoriasis were not available .…”

Section: Biologicsmentioning

confidence: 99%

Systemic treatments in paediatric psoriasis: a systematic evidence‐based update

Geel

Mul

Jager

et al. 2014

Acad Dermatol Venereol

View full text Add to dashboard Cite

In 2008, a systematic review revealed that evidence-based data on efficacy and safety of treatments in paediatric psoriasis are scarce and with low level of evidence. In recent years, publications on this topic have increased exponentially. To present a systematic, evidence-based update on the efficacy and safety of systemic treatments in paediatric psoriasis and to provide treatment recommendations, an update of the previous review was performed. PubMed, EMBASE and the Cochrane Controlled Clinical Trial Register were searched between January 2007 and March 2014 for all available literature on efficacy and safety of all systemic treatments in paediatric psoriasis. The levels of evidence were determined on the Oxford Centre for Evidence-based Medicine Levels of Evidence. The newly retrieved evidence was combined with the evidence available in the former review. Fifty-two studies were included: 36 from the former review, plus 16 new articles. New evidence on induction therapy was mainly available on fumaric acid esters (FAEs), which are shown to be effective in a subgroup of patients. Long-term (96 weeks) safety and efficacy data on etanercept were found. Prospective studies are scarce. Most conclusions are formulated on studies with low level of evidence. Of the conventional systemic treatments, methotrexate still has the most evidence albeit in a low number of patients and with a low level of evidence. FAEs seem to be effective in a subgroup of patients, with gastro-intestinal complaints, flushes and temporary shifts in leucocyte counts and liver enzymes being the main side-effects. Etanercept has still accumulated most evidence of the available systematic treatments, with a large efficacy and reassuring safety profile in a 96-week follow-up.

show abstract

Psoriatic Juvenile Idiopathic Arthritis Associated with Uveitis: A Case Report

Cited by 6 publications

References 20 publications

Adalimumab in the Treatment of Immune-Mediated Diseases

Adalimumab in the Treatment of Immune-Mediated Diseases

Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities

Systemic treatments in paediatric psoriasis: a systematic evidence‐based update

Contact Info

Product

Resources

About